TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN . Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n =1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 (TM6SF2) is also reportedly associated with MASLD and sometimes MASH (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, the splice variant rs72613567 in the Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17B13) gene has been identified as protective against MASH, with HSD17B13 potentially contributing to MASH fibrosis by promoting pyrimidine catabolism (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Purcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citation
Cited by
Items 101–200 of 623
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
Ajmera, V. H., Terrault, N. A., & Harrison, S. A. (2017) · Hepatology · doi:10.1002/hep.29055 · Cited by 137
“A genetic variant in patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with increased risk of steatosis, fibrosis, and HCC in both NAFLD and ALD, 24) and a coding variant in transmembrane 6 superfamily member 2 (TM6SF2) is associated with increased risk of steatosis and fibrosis in NAFLD((25,26)) a…”
BackgroundThe Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
Iqbal, U., Perumpail, B. J., Akhtar, D., Kim, D., & Ahmed, A. (2019) · Medicines · doi:10.3390/medicines6010041 · Cited by 136
“These include TM6SF2, PNPLA3, NCAN, and PPP1R3B genes that increase the heritability of NAFLD to up to 27% [15–21].”
BackgroundInfluentialStrnad, P., Buch, S., Hamesch, K., Fischer, J., Rosendahl, J., Schmelz, R., Brueckner, S., Brosch, M., Heimes, C. V., Woditsch, V., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316228 · Cited by 137
Xia, M.-F., Bian, H., & Gao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00877 · Cited by 132
Yang, J., Trépo, E., Nahon, P., Cao, Q., Moreno, C., Letouzé, É., Imbeaud, S., Gustot, T., Deviere, J. M. E., Debette, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31910 · Cited by 144
Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
Sookoian, S., Pirola, C. J., Valenti, L., & Davidson, N. O. (2020) · Hepatology · doi:10.1002/hep.31229 · Cited by 127
“(95) Pathways related to the regulation of beta-cell development were highly associated with NAFLD, taBle 1.”
BackgroundInfluentialMERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease
Petta, S., Valenti, L. V. C., Marra, F., Grimaudo, S., Tripodo, C., Bugianesi, E., Cammà, C., Cappon, A., Marco, V. D., Maira, G. D., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.016 · Cited by 127
“In all models, according to literature data, we compared patients homozygous for MERTK A protective allele to all other variants [14], the TM6SF2 variant was coded in a dominant genetic model because of its relatively low allele frequency [12,13], and an additive model was used for PNPLA3 [11].”
Luukkonen, P. K., Zhou, Y., Haridas, P. A. N., Dwivedi, O. P., Hyötyläinen, T., Ali, A., Juuti, A., Leivonen, M., Tukiainen, T., Ahonen, L. L., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.014 · Cited by 158
“Since these changes resemble those of carriers of the TM6SF2 E167K gene variant (2-13), we hypothesized that reduced”
InfluentialSelf-citationMASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Phoolchund, A. G. S., & Khakoo, S. I. (2024) · Cancers · doi:10.3390/cancers16020259 · Cited by 164
“Not significantly associated with HCC in multivariate analysis [49] Abbreviations: HCC, hepatocellular carcinoma; MASLD, metabolic dysfunction associated steatotic liver disease; T2DM, type 2 diabetes mellitus.”
BackgroundNonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges
Goldner, D. L., & Lavine, J. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.048 · Cited by 149
Eslam, M., Mangia, A., Berg, T., Chan, H. L. Y., Irving, W. L., Dore, G. J., Abate, M. L., Bugianesi, E., Adams, L. A., Najim, M. A. M., et al. (2016) · Hepatology · doi:10.1002/hep.28475 · Cited by 122
“While there is evidence suggesting a role for this variant in NAFLD-associated liver fibrosis, this finding is not unequivocal((10-14)) and is debatable in the case of chronic hepatitis C (CHC).”
BackgroundInfluentialStickel, F., Buch, S., Nischalke, H. D., Weiss, K. H., Gotthardt, D., Fischer, J., Rosendahl, J., Marot, A., Elamly, M., Casper, M., et al. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0041-8 · Cited by 118
Genetics of nonalcoholic fatty liver disease
Dongiovanni, P., & Valenti, L. V. C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.018 · Cited by 133
“spectrum of liver damage associated with NAFLD, including NASH, hepatocellular ballooning and necroinflammation, and clinically significant fibrosis [32,92].”
BackgroundZhou, Y., Llauradó, G., Orešič, M., Hyötyläinen, T., Orho-Melander, M., & Yki-Järvinen, H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.010 · Cited by 112
Tanabe, H., Saito, H., Kudo, A., Machii, N., Hirai, H., Maimaituxun, G., Tanaka, K., Masuzaki, H., Watanabe, T., Asahi, K., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072083 · Cited by 112
Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond
Krawczyk, M., Liebe, R., & Lammert, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.053 · Cited by 109
Aller, R., Fernández‐Rodríguez, C., Iacono, O. L., Bañares, R., Abad, J., Carrión, J. A., García‐Monzón, C., Caballería, J., Berenguer, M., Rodríguez‐Perálvarez, M., et al. (2018) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2017.12.003 · Cited by 132
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer
Newberry, E. P., Hall, Z., Xie, Y., Molitor, E. A., Bayguinov, P. O., Strout, G. W., Fitzpatrick, J. A. J., Brunt, E. M., Griffin, J. L., & Davidson, N. O. (2021) · Hepatology · doi:10.1002/hep.31771 · Cited by 106
Koo, B. K., Joo, S. K., Kim, D., Bae, J. M., Park, J. H., Kim, J. H., & Kim, W. K. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14056 · Cited by 107
Genetic and Epigenetic Modifiers of Alcoholic Liver Disease
Meroni, M., Longo, M., Rametta, R., & Dongiovanni, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123857 · Cited by 105
Yang, J., Trépo, E., Nahon, P., Cao, Q., Moreno, C., Letouzé, E., Imbeaud, S., Bayard, Q., Gustot, T., Deviere, J., et al. (2019) · Hepatology · doi:10.1002/hep.30623 · Cited by 107
Nonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review
Severson, T. J., Besur, S. V., & Bonkovsky, H. L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6742 · Cited by 116
Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
Kutlu, Ö., Kaleli, H. N., & Ozer, E. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8543763 · Cited by 115
“11) has been reported to correlate with steatosis and advanced fibrosis in NASH patients [24, 25], independently of diabetes, obesity, or PNPLA3 genotype.”
BackgroundNatural history of NASH and HCC
Negro, F. (2020) · Liver International · doi:10.1111/liv.14362 · Cited by 113
Hou, T., Tian, Y., Cao, Z., Zhang, J., Feng, T., Tao, W., Sun, H., Wen, H., Lu, X., Zhu, Q., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.018 · Cited by 112
Zhou, Y. J., Ding, Y., Zhang, J.-L., Zhang, P., Wang, J.-Q., & Li, Z.-H. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.035 · Cited by 104
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 118
“Thus, the TM6SF2 rs58542926 C > T (E167K) allele influences hepatic fibrosis irrespective of confounding risk factors such as obesity, T2DM, and age [72].”
BackgroundSchwantes‐An, T., Darlay, R., Mathurin, P., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., Gleeson, D., Thompson, A., et al. (2021) · Hepatology · doi:10.1002/hep.31535 · Cited by 99
Self-citationGenome‐Wide Association Study of NAFLD Using Electronic Health Records
Fairfield, C. J., Drake, T. M., Pius, R., Bretherick, A. D., Campbell, A., Clark, D. W., Fallowfield, J. A., Hayward, C., Henderson, N. C., Joshi, P. K., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1805 · Cited by 97
Noninvasive fatty liver markers predict liver disease mortality in the U.S. population
Unalp‐Arida, A., & Ruhl, C. E. (2016) · Hepatology · doi:10.1002/hep.28390 · Cited by 96
“(41) This finding has been independently validated and extended to include associations with hepatic fibrosis progression and a lower risk of CVD.(42-44) TM6SF2 has been determined to play a role in very-low-density lipoprotein secretion from liver into serum and normal gene activity results in increased serum lipid a…”
ResultXu, R., Pan, J., Zhou, W., Ji, G., & Dang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113331 · Cited by 114
Genetics of liver disease: From pathophysiology to clinical practice
Karlsen, T. H., Lammert, F., & Thompson, R. J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.025 · Cited by 94
“The effect is modified by other genetic risk factors such as TM6SF2 p.E167K [82] but the population-attributable risk for fatty liver disease is highest for PNPLA3 p.I148M [81].”
BackgroundNonalcoholic fatty liver disease: new treatments
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 89
Self-citationHepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice
Fan, Y., Lu, H., Guo, Y., Zhu, T., Garcia-Barrio, M. T., Jiang, Z., Willer, C. J., Zhang, J., & Chen, Y. E. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.005 · Cited by 92
TM6SF2 rs58542926 impacts lipid processing in liver and small intestine
O'Hare, E. A., Yang, R., Yerges‐Armstrong, L. M., Sreenivasan, U., McFarland, R., Leitch, C. C., Wilson, M. H., Narina, S., Gorden, A., Ryan, K. A., et al. (2017) · Hepatology · doi:10.1002/hep.29021 · Cited by 92
A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
Ahadi, M., Molooghi, K., Masoudifar, N., Namdar, A. B., Vossoughinia, H., & Farzanehfar, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15353 · Cited by 108
Falleti, E., Cussigh, A., Cmet, S., Fabris, C., & Toniutto, P. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.09.009 · Cited by 93
Prussick, R. B., & Miele, L. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16239 · Cited by 100
TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?
Kahali, B., Liu, Y., Daly, A. K., Day, C. P., Anstee, Q. M., & Speliotes, E. K. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.038 · Cited by 89
Self-citationGrandone, A., Cozzolino, D., Marzuillo, P., Cirillo, G., Sessa, A. D., Ruggiero, L., Palma, M. R. D., Perrone, L., & del Giudice, E. M. (2015) · Pediatric Obesity · doi:10.1111/ijpo.12032 · Cited by 86
Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
Pirola, C. J., & Sookoian, S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i15.1601 · Cited by 85
Yang, M., Liu, Q., Huang, T., Tan, W., Qu, L., Chen, T., Pan, H., Chen, L., Liu, J., Wong, C.-W., et al. (2020) · Theranostics · doi:10.7150/thno.47037 · Cited by 84
“Intriguingly, dysfunctional VLDL synthesis and release is behind the transition from simple steatohepatosis to steatohepatitis [15-18].”
BackgroundShared genetic effects between hepatic steatosis and fibrosis: A prospective twin study
Cui, J., Chen, C., Lo, M., Schork, N., Bettencourt, R., Gonzalez, M. P., Bhatt, A., Hooker, J., Shaffer, K., Nelson, K. E., et al. (2016) · Hepatology · doi:10.1002/hep.28674 · Cited by 82
“13) Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.”
BackgroundInfluentialGellert‐Kristensen, H., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Stender, S. (2020) · Hepatology · doi:10.1002/hep.30799 · Cited by 80
Genetic background in nonalcoholic fatty liver disease: A comprehensive review
Macaluso, F. S., Maida, M. F., & Petta, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11088 · Cited by 95
Choudhary, N. S., & Duseja, A. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.09.06 · Cited by 80
“This association was independent of age, BMI, T2DM and PNPLA3 rs738409 genotype (42).”
BackgroundMancina, R. M., Matikainen, N., Maglio, C., Söderlund, S., Lundbom, N., Hakkarainen, A., Rametta, R., Mozzi, E., Fargion, S., Valenti, L., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4464 · Cited by 78
Ayonrinde, O. T. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100261 · Cited by 75
Liu, J., Jiang, S., Zhao, Y., Sun, Q., Zhang, J., Shen, D., Wu, J., Shen, N., Fu, X., Sun, X., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5131 · Cited by 72
“The patatin-like phospholipase domain containing 3 gene (Pnpla3) and TM6SF2 have been identified as potential regulators of the progression of NAFLD from steatosis to fibrosis and HCC [31,32].”
BackgroundHepatocellular carcinoma and non-alcoholic fatty liver disease
Golabi, P., Rhea, L. P., Henry, L. L., & Younossi, Z. M. (2019) · Hepatology International · doi:10.1007/s12072-019-09995-8 · Cited by 79
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 84
Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics
Sookoian, S., & Pirola, C. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679920 · Cited by 70
Yoneda, M., Imajo, K., Takahashi, H., Ogawa, Y., Eguchi, Y., Sumida, Y., Yoneda, M., Kawanaka, M., Saito, S., Tokushige, K., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1414-2 · Cited by 73
“AAR Aspartate aminotransferase-to-alanine aminotransferase ratio AASLD American Association for the Study of Liver Diseases AGEs Advanced glycation end products ARFI Acoustic radiation force impulse BMI Body mass index FIB-4 Fibrosis-4 HCC Hepatocellular carcinoma ICC Intra-class correlation coefficient NAFL Nonalcoho…”
BackgroundInfluentialGenetic Insights for Drug Development in NAFLD
Eslam, M., & George, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.002 · Cited by 69
Combined alcoholic and non-alcoholic steatohepatitis
Wandji, L. C. N., Gnemmi, V., Mathurin, P., & Louvet, A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100101 · Cited by 78
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Campos-Murguía, A., Ruiz‐Margáin, A., González-Regueiro, J. A., & Macías‐Rodríguez, R. U. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i39.5919 · Cited by 84
Mitrovic, B., Obradovic, M. M., Gluvic, Z. M., Radunovic, M. L., Rizzo, M., Banach, M., & Isenović, E. R. (2022) · Archives of Medical Science · doi:10.5114/aoms/150639 · Cited by 131
Degasperi, E., Galmozzi, E., Pelusi, S., D’Ambrosio, R., Soffredini, R., Borghi, M., Perbellini, R., Facchetti, F., Iavarone, M. A., Sangiovanni, A., et al. (2020) · Hepatology · doi:10.1002/hep.31500 · Cited by 69
“ALT, U/L 71 (8-770) 74 (8-770) 59 (15-209)”
BackgroundInfluentialNon-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes
Scapaticci, S., D’Adamo, E., Mohn, A., Chiarelli, F., & Giannini, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.639548 · Cited by 84
Genetics Is of the Essence to Face NAFLD
Meroni, M., Longo, M., Tria, G., & Dongiovanni, P. (2021) · Biomedicines · doi:10.3390/biomedicines9101359 · Cited by 73
“reported that the T risk allele conferred an increased predisposition to develop NAFLD-related advanced fibrosis in two independent cohort regardless of other confounders as gender, sex, BMI, T2D and PNPLA3 rs738409 genotype [101].”
BackgroundGenetic and epigenetic mechanisms of NASH
Eslam, M., & George, J. (2015) · Hepatology International · doi:10.1007/s12072-015-9689-y · Cited by 72
“Recent data also suggest that the TM6SF2 rs58542926 variant is independently associated with the severity of NAFLD-associated hepatic fibrosis/cirrhosis and might increase the risk to HCC, though it was not associated with hepatic inflammation [11, 12].”
BackgroundChildhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study
Suomela, E., Oikonen, M., Pitkänen, N., Ahola‐Olli, A., Virtanen, J. M., Parkkola, R. K., Jokinen, E. V., Laitinen, T. P., Hutri‐Kähönen, N., Kähönen, M. A. P., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.020 · Cited by 67
Host – hepatitis C viral interactions: The role of genetics
Heim, M. H., Bochud, P., & George, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.037 · Cited by 72
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology · doi:10.1002/hep.32427 · Cited by 65
Self-citationWang, X., Liu, Z., Wang, K., Wang, Z., Sun, X., Zhong, L., Deng, G., Song, G., Sun, B., Peng, Z., et al. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00140 · Cited by 68
Geh, D., Manas, D., & Reeves, H. L. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.08.08 · Cited by 69
“Finally, underpinning the range in disease severity, patient genetic factors, with variations in liver regulatory genes such as PNPLA3, TM6SF2 and MBOAT7, are believed to play a key role not just in NAFLD progression, but also in determining an individual’s risk of developing NAFLD-HCC (41-44).”
BackgroundSelf-citationA “systems medicine” approach to the study of non-alcoholic fatty liver disease
Petta, S., Valenti, L. V. C., Bugianesi, E., Targher, G., Bellentani, S., Bonino, F., Ferrannini, E., Loguercio, C., Lonardo, A., Marra, F., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.10.027 · Cited by 70
“The TM6SF2-E167K variant was also associated with NAFLD [53]; it favours progression to NASH and fibrosis by impairing the secretion of very low density lipoproteins in hepatocytes, but protecting from atherosclerosis [59,77].”
BackgroundMazo, D. F. D. C., Malta, F. D. M., Stefano, J. T., Salles, A. P. M., Gomes‐Gouvêa, M. S., Nastri, A. C. D. S. S., Almeida, J. R. S., Pinho, J. R. R., Carrilho, F. J., & de Oliveira, C. P. M. S. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.10.004 · Cited by 68
“Interestingly, TM6SF2 SNP loss of function leads to triglyceride retention in the liver and decreases the likelihood of hypertriglyceridemia and cardiovascular events [11,19,20].”
BackgroundTM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease
Sanchez-Pulido, L., & Ponting, C. P. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00439 · Cited by 63
Gutiérrez‐Cuevas, J., Lucano‐Landeros, S., López-Cifuentes, D., Santos, A., & Armendáriz‐Borunda, J. (2022) · Cancers · doi:10.3390/cancers15010023 · Cited by 68
“In addition, for each of the three variants, subjects carrying two risk alleles have a 2- to 4-fold higher risk of developing fibrosis, cirrhosis, and HCC compared to those without these risk alleles [78,81,82].”
BackgroundTalamantes, S., Lisjak, M., Gilglioni, E. H., Llamoza-Torres, C. J., Ramos‐Molina, B., & Gurzov, E. N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100811 · Cited by 71
NAFLD-Associated HCC: Progress and Opportunities
Geh, D., Anstee, Q. M., & Reeves, H. L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272213 · Cited by 61
“…TM6SF2 rs58542926 is again associated with NAFLD progression to fibrosis but has conflicting reports of its independent association with HCC. 42 Although a recent meta-analysis of 5 studies including a total of 6873 patients has confirmed an independent association, 46 the requirement for…”
Self-citationWard, L. D., Tu, H.-C., Quenneville, C. B., Tsour, S., Flynn-Carroll, A. O., Parker, M. M., Deaton, A. M., Haslett, P. A. J., Lotta, L. A., Verweij, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24563-1 · Cited by 59
Guerra, S., Mocciaro, G., & Gastaldelli, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13695 · Cited by 65
Ehrhardt, N., Doche, M. E., Chen, S., Mao, H. Z., Walsh, M. T., Bedoya, C., Guindi, M., Xiong, W., Ignatius Irudayam, J., Iqbal, J., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx159 · Cited by 60
“Genetic variation in the human TM6SF2 gene is associated with pathological features of NAFLD including steatosis, steatohepatitis and fibrosis (2,3,10,12,13).”
BackgroundNascimbeni, F., Ballestri, S., Machado, M. V., Mantovani, A., Cortez‐Pinto, H., Targher, G., & Lonardo, A. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1415756 · Cited by 64
“Other genetic polymorphisms might also promote liver histopathological changes in NAFLD, such as transmembrane 6 superfamily member 2 (TM6SF2) [95,96], membrane-bound”
BackgroundMilano, M., Aghemo, A., Mancina, R. M., Fischer, J., Dongiovanni, P., Nicola, S. D., Fracanzani, A. L., D’Ambrosio, R., Maggioni, M., Francesco, R. D., et al. (2015) · Hepatology · doi:10.1002/hep.27811 · Cited by 59
“On the other hand, hepatocellular lipid retention in E167K variant carriers triggers hepatic inflammation and fibrogenesis in individuals at risk of nonalcoholic steatohepatitis.(24-26) The aim of this study was to assess the impact of the TM6SF2 E167K variant on severity of steatosis, necroinflammation, and fibrosis…”
BackgroundResultTakahashi, Y., Dungubat, E., Kusano, H., & Fukusato, T. (2023) · Biomedicines · doi:10.3390/biomedicines11102761 · Cited by 64
Grgurević, I., Božin, T., Mikuš, M., Kukla, M., & O’Beirne, J. P. (2021) · Cancers · doi:10.3390/cancers13225844 · Cited by 61
“patients, independently of diabetes mellitus (DM), obesity or PNPLA3 variant [33,34].”
BackgroundNoninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Buzzetti, E., Lombardi, R., Luca, L. D., & Tsochatzis, E. A. (2015) · International Journal of Endocrinology · doi:10.1155/2015/343828 · Cited by 60
Pennisi, G., Celsa, C., Giammanco, A., Spatola, F., & Petta, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225613 · Cited by 55
“Similar to the PNPLA3 I148M variant, the rs58542926 C > T variant in the TM6SF2 gene, encoding an E167K mutation, was shown to be associated with hepatic steatosis and also with increased risk of progressive liver disease and fibrosis [32–35], but its direct role in HCC predisposition is disputed [35,36].”
ResultSookoian, S. C., Flichman, D., Garaycoechea, M. E., Gazzi, C., Martino, J. S., Castaño, G. O., & Pirola, C. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-23453-9 · Cited by 56
TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis
Basytė-Bacevičė, V., Skiecevičienė, J., Valantienė, I., Šumskienė, J., Petrenkienė, V., Kondrackienė, J., Petrauskas, D., Lammert, F., & Kupčinskas, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061277 · Cited by 57
“TM6SF2 variant rs58542926 has also been associated with an increased risk of developing advanced hepatic fibrosis and cirrhosis in patients with non-alcoholic fatty liver disease (NAFLD) [13].”
BackgroundInfluentialCoppola, N., Zampino, R., Cirillo, G., Stanzione, M., Macera, M., Boemio, A., Grandone, A., Pisaturo, M., Marrone, A., Adinolfi, L. E., et al. (2015) · Liver International · doi:10.1111/liv.12781 · Cited by 54
“No association was found between the TM6SF2 variants and severe necroinflammation or severe fibrosis, whereas in a recent study on 1074 patients with histologically proven NAFLD the TM6SF2 E167K polymorphism was associated with severe liver fibrosis (13).”
BackgroundInfluentialThe genetic backgrounds in nonalcoholic fatty liver disease
Seko, Y., Yamaguchi, K., & Itoh, Y. (2018) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-018-0841-9 · Cited by 58
“A validation study revealed the association of TM6SF2 with hepatic fibrosis [54].”
BackgroundBurden of non‐alcoholic fatty liver disease in Australia
Mahady, S. E., & Adams, L. A. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14270 · Cited by 54
Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
Hagström, H., Kechagias, S., & Ekstedt, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13343 · Cited by 52
Alpinetin: A Review of Its Pharmacology and Pharmacokinetics
Zhao, G., Tong, Y. A., Luan, F., Zhu, W., Zhan, C., Qin, T., An, W., & Zeng, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.814370 · Cited by 60
“Non-alcoholic fatty liver disease (NAFLD) is reputed as an elementary public health issue globally, which accelerates the pathological progress of various disease such as type II diabetes and cardiovascular disorder (Liu et al., 2014; Sheldon et al., 2014).”
BackgroundImmunometabolism and metainflammation in obesity
Romantsova, T. I., & Sych, Y. P. (2019) · Obesity and metabolism · doi:10.14341/omet12218 · Cited by 68
Manchiero, C., Nunes, A. K. D. S., Magri, M. C., Dantas, B. P., Mazza, C. C., Barone, A. A., & Tengan, F. M. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2887-6 · Cited by 51
“Wang X, Liu Z, Wang K, Wang Z, Sun X, Zhong L, et al. Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population.”
ResultInfluentialHepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play
Charrez, B., Qiao, L., & Hebbard, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2494 · Cited by 50
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
Chrysavgis, L., Ztriva, E., Protopapas, A. A., Τζιόμαλος, Κ., & Cholongitas, Ε. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i42.6514 · Cited by 54
Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
Dorairaj, V., Sulaiman, S. A., Abu, N., & Murad, N. A. A. (2021) · Biomedicines · doi:10.3390/biomedicines10010015 · Cited by 59
Review article: emerging anti‐fibrotic therapies in the treatment of non‐alcoholic steatohepatitis
Noureddin, M., Anstee, Q. M., & Loomba, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13620 · Cited by 51
Self-citationRaksayot, M., Chuaypen, N., Khlaiphuengsin, A., Pinjaroen, N., Treeprasertsuk, S., Poovorawan, Y., Tanaka, Y., & Tangkijvanich, P. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-01533-x · Cited by 54
Tang, S., Zhang, J., Mei, T., Guo, H.-Q., Wei, X., Zhang, W., Liu, Y., Liang, S., Fan, Z.-P., Ma, L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6173-4 · Cited by 51
Self-citationWang, X., Liu, Z., Peng, Z., & Liu, W. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.040 · Cited by 49
López‐Pastor, A. R., Infante‐Menéndez, J., Escribano, Ó., & Gómez‐Hernández, A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.527059 · Cited by 59
Kang, H., You, H. J., Lee, G., Lee, S. H., Yoo, T., Choi, M., Joo, S. K., Park, J. H., Chang, M. S., Lee, D. H., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2078612 · Cited by 48
Metadata
- Authors
- Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., Donaldson, P., Aithal, G. P., Francque, S., Van Gaal, L., Clement, K., Ratziu, V., Dufour, J.-F., Day, C. P., Daly, A. K., & Anstee, Q. M.
- Affiliations
- Newcastle University (GB)
- Addenbrooke's Hospital (GB)
- University Hospital of Bern (CH)
- Inserm (FR)
- Nottingham University Hospitals NHS Trust (GB)
- Antwerp University Hospital (BE)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Anstee, Quentin M.
- ORCID
- Venue
- Nature Communications
- Published
- 2014-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 4309-4309
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4279183
- OpenAlex
- W2038831349
- Cited by
- 623
- References
- 45
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 50 · 2023: 51 · 2022: 56 · 2021: 61 · 2020: 82 · 2019: 49 · 2018: 50 · 2017: 45 · 2016: 54 · 2015: 50 · 2014: 11
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (FP7/2007–2013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 241762)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- TM6SF2, rs58542926, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, non-synonymous polymorphisms, genetic association, hepatic triglyceride content, neurocan, chromosome 19, steatohepatitis, PNPLA3, disease progression
- MeSH terms
- Adult, Aged, Alleles, Female, Genotype, Heterozygote, Humans, Liver, Liver Cirrhosis, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Cohort Studies, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lectins, C-Type, Neurocan, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.